Catalent Increases Spray Drying Capacity at San Diego Facility

Article

PTSM: Pharmaceutical Technology Sourcing and Management

PTSM: Pharmaceutical Technology Sourcing and ManagementPTSM: Pharmaceutical Technology Sourcing and Management-05-02-2017
Volume 12
Issue 5

The company increased capabilities at its Pharmatek San Diego facility in response to market demand for solubility enhancement solutions.

On April 25, 2017, Catalent Pharma Solutions announced that it is increasing spray drying capacity at its Pharmatek, San Diego, CA facility with the installation of an additional GEA Niro Mobile Minor unit. The expanded capabilities are being introduced in response to market demand for solubility enhancement solutions and are expected to be validated for cGMP use by the end of April 2017. To further support the development of spray-dried dispersions, Catalent has also installed a third Gerties Mini-Pactor, a high-pressure roller compactor, at its San Diego site. The compactor is expected to be validated by early May 2017.

In a statement, Barry Littlejohns, president of Catalent’s Drug Delivery Solutions business noted that this is the “first of several strategic investments” that the company has planned for the San Diego facility. Catalent’s Pharmatek site in San Diego is a cGMP site that employs nearly 200 people, providing development and analytical services for more than 120 molecules annually. The facility comprises 68,000 square feet of laboratory, manufacturing, and support space, with two analytical labs, two formulation labs, four engineering rooms, and nine certified ISO class 8 manufacturing suites. The site also features 18,000 square feet of laboratory, manufacturing, and support space dedicated to development and manufacturing of highly-potent compounds.

Catalent acquired Pharmatek Laboratories in September 2016 to add early-phase drug development capabilities from preclinical to clinic, bring spray drying into Catalent’s portfolio of drug formulation and delivery technologies, and expand Catalent’s capability for handling highly potent compounds.

Source: Catalent

Recent Videos
Behind the Headlines episode 6
CPHI Milan 2024: Highlighting the Benefits of Integrated Services
Behind the Headlines episode 5
Buy, Sell, Hold: Cell and Gene Therapy
Buy, Sell, Hold: Cell and Gene Therapy
Buy, Sell, Hold: Cell and Gene Therapy
Related Content